Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Standard outcome measures for thymic malignancies.

Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr.

J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1691-7. doi: 10.1097/JTO.0b013e3182254ac1. No abstract available.

2.

Standard outcome measures for thymic malignancies.

Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr.

J Thorac Oncol. 2010 Dec;5(12):2017-23. doi: 10.1097/JTO.0b013e3181f13682. Review.

3.

[Standard outcome measures for thymic malignancies].

Huang J, Detterbeck FC, Wang Z, Loehrer PJ.

Zhongguo Fei Ai Za Zhi. 2014 Feb;17(2):122-9. doi: 10.3779/j.issn.1009-3419.2014.02.10. Review. Chinese. No abstract available.

4.

Do thymic malignancies respond to target therapies?

Hu B, Rong H, Han Y, Li Q.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):855-9. doi: 10.1093/icvts/ivv040. Epub 2015 Mar 8. Review.

PMID:
25754373
5.

Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.

Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA.

Lung Cancer. 2015 Jan;87(1):34-8. doi: 10.1016/j.lungcan.2014.11.006. Epub 2014 Nov 15.

PMID:
25443273
6.

Insulin-like growth factor-1 receptor expression in thymic malignancies.

Girard N, Teruya-Feldstein J, Payabyab EC, Riely GJ, Rusch VW, Kris MG, Zakowski MF.

J Thorac Oncol. 2010 Sep;5(9):1439-46. doi: 10.1097/JTO.0b013e3181e392a8.

7.

The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies.

Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K; Staging and Prognostic Factors Committee.; Members of the Advisory Boards.; Participating Institutions of the Thymic Domain..

J Thorac Oncol. 2013 Dec;8(12):1467-73. doi: 10.1097/JTO.0000000000000017.

8.

Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy.

Okuma Y, Saito M, Hosomi Y, Sakuyama T, Okamura T.

J Cancer Res Clin Oncol. 2015 Feb;141(2):323-31. doi: 10.1007/s00432-014-1800-6. Epub 2014 Aug 22. Review.

9.

Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread.

Refaely Y, Simansky DA, Paley M, Gottfried M, Yellin A.

Ann Thorac Surg. 2001 Aug;72(2):366-70.

PMID:
11515868
10.

Prognostic grading after complete resection for thymic malignancies.

Lococo F, Cafarotti S, Cesario A, Dall'Armi V, Cusumano G, Lauriola L, Frederic M, Evoli A, Margaritora S, Granone P.

Eur Rev Med Pharmacol Sci. 2015 Aug;19(15):2882-91.

11.

Radiotherapy for thymoma and thymic carcinoma.

Fuller CD, Housman DM, Thomas CR.

Hematol Oncol Clin North Am. 2008 Jun;22(3):489-507. doi: 10.1016/j.hoc.2008.03.012. Review.

PMID:
18514129
12.

MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.

Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T, Yamamoto N.

Virchows Arch. 2011 May;458(5):615-20. doi: 10.1007/s00428-011-1041-x. Epub 2011 Jan 21.

PMID:
21253760
13.

Development of the international thymic malignancy interest group international database: an unprecedented resource for the study of a rare group of tumors.

Huang J, Ahmad U, Antonicelli A, Catlin AC, Fang W, Gomez D, Loehrer P, Lucchi M, Marom E, Nicholson A, Ruffini E, Travis W, Van Schil P, Wakelee H, Yao X, Detterbeck F; International Thymic Malignancy Interest Group International Database Committee and Contributors..

J Thorac Oncol. 2014 Oct;9(10):1573-8. doi: 10.1097/JTO.0000000000000269. Erratum in: J Thorac Oncol. 2014 Dec;9(12):1804.

14.

Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center.

Okuma Y, Hosomi Y, Watanabe K, Yamada Y, Horio H, Maeda Y, Okamura T, Hishima T.

BMC Cancer. 2014 May 20;14:349. doi: 10.1186/1471-2407-14-349.

15.

Thymic and adenotonsillar enlargement after successful treatment of malignancies.

Oguz A, Karadeniz C, Citak EC, Conly NA, Ileri F, Boyunaga O, Okur V, Uluoglu O.

Pediatr Hematol Oncol. 2005 Jul-Aug;22(5):423-35.

PMID:
16020133
16.

Thymic tumors: relevant molecular data in the clinic.

Girard N.

J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S291-5. doi: 10.1097/JTO.0b013e3181f209b9. Review.

17.

The International Thymic Malignancy Interest Group thymic initiative: a state-of-the-art study of thymic malignancies.

Detterbeck F, Korst R.

Semin Thorac Cardiovasc Surg. 2014 Winter;26(4):317-22. doi: 10.1053/j.semtcvs.2015.02.002. Epub 2015 Feb 7. Review.

PMID:
25837546
18.

The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.

Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, Filosso PL, Frazier AA, Giaccone G, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson AG, Okumura M, Ruffini E, Van Schil P; Staging and Prognostic Factors Committee.; Members of the Advisory Boards.; Participating Institutions of the Thymic Domain..

J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S65-72. doi: 10.1097/JTO.0000000000000290.

19.

The role of chemotherapy in advanced thymoma.

Schmitt J, Loehrer PJ Sr.

J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S357-60. doi: 10.1097/JTO.0b013e3181f21129. Review.

20.

Phase II study of Amrubicin combined with carboplatin for thymic carcinoma and invasive thymoma: North Japan Lung Cancer group study 0803.

Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Hotta K, Nukiwa T.

J Thorac Oncol. 2014 Dec;9(12):1805-9. doi: 10.1097/JTO.0000000000000362.

Supplemental Content

Support Center